- Home
- SPNS vs GERN Comparison
SPNS vs GERN Comparison
Compare SPNS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- GERN
- Stock Information
- Founded
- SPNS 1982
- GERN 1990
- Country
- SPNS Israel
- GERN United States
- Employees
- SPNS N/A
- GERN N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SPNS Technology
- GERN Health Care
- Exchange
- SPNS Nasdaq
- GERN Nasdaq
- Market Cap
- SPNS 1.6B
- GERN 1.5B
- IPO Year
- SPNS 1992
- GERN 1996
- Fundamental
- Price
- SPNS $27.35
- GERN $1.56
- Analyst Decision
- SPNS Buy
- GERN Buy
- Analyst Count
- SPNS 4
- GERN 11
- Target Price
- SPNS $33.50
- GERN $5.80
- AVG Volume (30 Days)
- SPNS 140.7K
- GERN 14.9M
- Earning Date
- SPNS 05-07-2025
- GERN 05-01-2025
- Dividend Yield
- SPNS 3.48%
- GERN N/A
- EPS Growth
- SPNS 15.18
- GERN N/A
- EPS
- SPNS 1.29
- GERN N/A
- Revenue
- SPNS $542,379,000.00
- GERN $76,994,000.00
- Revenue This Year
- SPNS $4.49
- GERN $208.83
- Revenue Next Year
- SPNS $5.15
- GERN $57.49
- P/E Ratio
- SPNS $21.14
- GERN N/A
- Revenue Growth
- SPNS 5.40
- GERN 32386.92
- 52 Week Low
- SPNS $25.01
- GERN $1.46
- 52 Week High
- SPNS $41.22
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- SPNS 48.10
- GERN 31.37
- Support Level
- SPNS $26.77
- GERN $1.63
- Resistance Level
- SPNS $27.91
- GERN $1.89
- Average True Range (ATR)
- SPNS 0.50
- GERN 0.11
- MACD
- SPNS -0.03
- GERN 0.03
- Stochastic Oscillator
- SPNS 37.04
- GERN 0.37
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.